Pegaptanib (Macugen) v léčbě vlhké formy věkem podmíněné makulární degenerace, 1,5 leté výsledky
| Title in English | Pegaptanib (Macugen) in treatment of wet form of age related macular degeneration, 1.5 year results |
|---|---|
| Authors | |
| Year of publication | 2009 |
| MU Faculty or unit | |
| Citation | |
| Description | Pegaptanib (Macugen) is available in the Czech Republic for the treatment of neovascular age-related macular degeneration since April 2007. Pegaptanib is a de facto representative of the first agents that interact with anti-vascular growth factor (VEGF) and through the connection to a specific isoform VEGF165. It was presented 1.5-year data on the treatment of wet AMD by pegaptanib. |